Hypoxia-Regulated Secretion of IL-12 Enhances Antitumor Activity and Safety of CD19 CAR-T Cells in the Treatment of Diffuse Large B Cell Lymphoma

Scientists suggested that armed CD19 CARs with hypoxia-controlled interleukin (IL)-12 might be a promising and safer approach for treating Diffuse Large B cell Lymphoma.